[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632247":3},{"organization":4,"armGroups":7,"interventions":60,"overallOfficials":66,"centralContacts":72,"locations":78,"responsibleParty":113,"collaborators":115,"id":118,"slug":119,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":66,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":126,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":66,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":81,"whyStopped":66,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,15,19,23,27,31,35,39,42,46,50,53,56],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A1 (Global SAD): Cohort 1 - AZD1043 (Dose 1)","EXPERIMENTAL","Participants will receive a single dose of AZD1043 (Dose 1) or placebo.",[13,14],"Drug: AZD1043","Other: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part A1 (Global SAD): Cohort 2 - AZD1043 (Dose 2)","Participants will receive a single dose of AZD1043 (Dose 2) or placebo.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Part A1 (Global SAD): Cohort 3 - AZD1043 (Dose 3)","Participants will receive a single dose of AZD1043 (Dose 3) or placebo.",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Part A1 (Global SAD): Cohort 4 - AZD1043 (Dose 4)","Participants will receive a single dose of AZD1043 (Dose 4) or placebo.",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"Part A1 (Global SAD): Cohort 5 - AZD1043 (Dose 5)","Participants will receive a single dose of AZD1043 (Dose 5) or placebo.",[13,14],{"label":32,"type":10,"description":33,"interventionNames":34},"Part A1 (Global SAD): Cohort 6 - AZD1043 (Dose 6)","Participants will receive a single dose of AZD1043 (Dose 6) or placebo.",[13,14],{"label":36,"type":10,"description":37,"interventionNames":38},"Part A2 (Japanese SAD): Cohort 1 - AZD1043 (Dose X)","Japanese participants will receive a single dose of AZD1043 or placebo.",[13,14],{"label":40,"type":10,"description":37,"interventionNames":41},"Part A2 (Japanese SAD): Cohort 2 - AZD1043 (Dose Y)",[13,14],{"label":43,"type":10,"description":44,"interventionNames":45},"Part A3 (Chinese SAD): Cohort 1 - AZD1043 (Dose Z)","Chinese participants will receive a single dose of AZD1043 or placebo.",[13,14],{"label":47,"type":10,"description":48,"interventionNames":49},"Part B1 (Global MAD): Cohort 1 - AZD1043 (Dose A)","Participants will receive multiple doses of AZD1043 or placebo.",[13,14],{"label":51,"type":10,"description":48,"interventionNames":52},"Part B1 (Global MAD): Cohort 2 - AZD1043 (Dose B)",[13,14],{"label":54,"type":10,"description":48,"interventionNames":55},"Part B1 (Global MAD): Cohort 3 - AZD1043 (Dose C)",[13,14],{"label":57,"type":10,"description":58,"interventionNames":59},"Part B2 (Japanese MAD): Cohort 1 - AZD1043 (Dose D)","Japanese participants will receive multiple doses of AZD1043 or placebo.",[13,14],[61,67],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"DRUG","AZD1043","Single or multiple doses of AZD1043 will be administered.",[9,16,20,24,28,32,36,40,43,47,51,54,57],null,{"type":68,"name":69,"description":70,"armGroupLabels":71,"otherNames":66},"OTHER","Placebo","Matching placebo to AZD1043 will be administered.",[9,16,20,24,28,32,36,40,43,47,51,54,57],[73],{"name":74,"role":75,"phone":76,"phoneExt":66,"email":77},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[79,93,103],{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":66},"Research Site","RECRUITING","Glendale","California","91206","United States","US",{"type":88,"coordinates":89},"Point",[90,91],-118.25508,34.14251,{"lat":91,"lon":90},{"facility":80,"status":94,"city":95,"state":96,"zip":97,"country":85,"countryCode":86,"cosmosGeoPoint":98,"geoPoint":102,"contacts":66},"NOT_YET_RECRUITING","Brooklyn","Maryland","21225",{"type":88,"coordinates":99},[100,101],-76.60219,39.23039,{"lat":101,"lon":100},{"facility":80,"status":94,"city":104,"state":66,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":66},"Harrow","HA1 3UJ","United Kingdom","UK",{"type":88,"coordinates":109},[110,111],-0.33208,51.57835,{"lat":111,"lon":110},{"type":114,"investigatorFullName":66,"investigatorTitle":66,"investigatorAffiliation":66,"oldNameTitle":66,"oldOrganization":66},"SPONSOR",[116],{"name":117,"class":6},"Parexel","100632247","phase-1-a-study-to-investigate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-azd1043-in-healthy-adult-participants-living-with-overweight-andor-obesity-100632247",false,"NCT07511205","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and\u002For Obesity.","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and\u002For Intravenous Administration in Healthy Adult Participants Living With Overweight and\u002For Obesity.","Inclusion Criteria:\n\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.\n* Have a body mass index between 25 and 39.9 kg\u002Fm2 (Global cohorts \\[Parts A1 and B1\\]), or 23 and 39.9 kg\u002Fm2 (Japanese \\[Parts A2 and B2\\] and Chinese \\[Part A3\\] cohorts) inclusive and weigh at least 50 kg.\n* For the Parts A2 and B2, participants should be Japanese (natives of Japan or Japanese Americans), having both parents and 4 grandparents who are Japanese. This includes healthy second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.\n* For the Part A3, participants should be Chinese defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity to drugs of a similar class to AZD1043.\n* Has received prescription, non-prescription, or experimental medications for weight loss within 3 months prior to the Screening Visit.\n* History of psychosis or bipolar disorder or major depressive disorder within the past 2 years with the participant being clinically unstable.",true,"ALL","18 Years","65 Years",{"count":130,"type":131},104,"ESTIMATED","INTERVENTIONAL",[134],"PHASE1","The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and\u002For obesity, including participants of Japanese and Chinese descent.",[137,138],"Healthy Participants","Obesity",[140,141,142,143,144],"First time in human","Single ascending dose","Multiple ascending dose","Pharmacokinetics","Pharmacodynamics","2026-06-09",{"date":147,"type":148},"2026-06-10","ACTUAL",{"date":150,"type":148},"2026-03-30",{"date":152,"type":131},"2027-11-17",{"name":5,"class":6},3]